Lead Product(s) : Sinapultide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Ladenburg Thalmann & Co
Deal Size : $20.2 million
Deal Type : Public Offering
Details : Windtree intends to use the net proceeds from this offering to advance the study of KL4 surfactant to treat COVID-19 related lung injury; istaroxime acute heart failure phase 2b start-up activities;clinical development of AEROSURF;pre-clinical studies of...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 22, 2020
Lead Product(s) : Sinapultide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Ladenburg Thalmann & Co
Deal Size : $20.2 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?
Reset All
